Pinealon for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Pinealon for Health & Longevity

Created on 08/06/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A three-amino-acid peptide made in Russia to slow age-related decline. Laboratory work — most from the institute that profits from selling it — shows the molecule entering cells, binding genetic material, and reducing damage in stressed nerve cells. Human evidence is thin: small studies without placebo groups, one finding pointing the other way, and no regulator has approved it. (Full Review)

Protocol

The Russian oral course protocol
100 micrograms twice daily
One capsule, twice daily for 10 to 14 days, repeated two to three times per year. The only dosing for which any human outcome data exist.
The Western injectable protocol
No published dose
Subcutaneous, in a pulsed pattern rather than nightly, deliberately combined with 3,000 to 5,000 mg of oral glycine at bedtime.
Best time of day
Morning and midday, or evening
The Russian regimen splits doses morning and midday; the Western regimen concentrates the dose in the evening. No study has compared timing directly.
Time to effect
Reported sleep effects
Days to weeks
The most detailed personal account describes the full effect accumulating over four to six months of intermittent use.
Biological-age and adaptation indices
10 to 14 days
The published human protocols assess outcomes after a complete course, and the indices were measured at that point.
First-night effect
Not expected
Anyone expecting a first-night effect is either responding to a co-administered agent or to expectation.

Benefits

Contraindications
  • Pregnancy and lactation
  • Anyone under 18
  • Active malignancy, or malignancy in remission for less than five years
  • History of haematological malignancy or documented bone-marrow suppression
  • Active autoimmune disease requiring immunosuppression
  • Severe hepatic impairment (Child-Pugh Class C)
  • Advanced kidney disease (filtration rate below 30 mL/min/1.73 m²)
  • Untreated moderate-to-severe obstructive sleep apnoea (apnoea-hypopnoea index above 15 events per hour)
  • Safety-critical occupation during the first two weeks of use
  • Anyone who cannot obtain product with an independent certificate of analysis
    •
Key Interactions
  • Sedative-hypnotics and orexin antagonists (zolpidem, temazepam, suvorexant)
  • Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel, aspirin)
  • Large neutral amino acid transporter substrates (levodopa, gabapentin, baclofen, levothyroxine)
  • Dipeptidyl peptidase-4 inhibitors (sitagliptin, linagliptin, saxagliptin)
  • Angiotensin-converting enzyme inhibitors (enalapril, lisinopril, ramipril)
  • Over-the-counter sedatives and sleep aids (melatonin, diphenhydramine, doxylamine, valerian)
  • Over-the-counter analgesics (ibuprofen, naproxen, aspirin)
  • Glycine (3,000 to 5,000 mg at bedtime)
  • Other supplements with additive sedative or serotonergic effects (magnesium glycinate, L-Theanine, ashwagandha, 5-HTP, St John's wort)
  • Other short peptides in the same family (Epitalon, Vesugen, Cortagen, Thymalin)
  • High-dose amino acid supplements (branched-chain amino acids, leucine)
    •

Risk & Side Effects

  • Low: Product adulteration, substitution and misidentification; injection-site reactions and infection risk; pro-oxidant activity and suppression of blood-forming progenitors
  • Speculative: Transient headache and gastrointestinal discomfort; vivid dreams, late-dose insomnia and transient dizziness; theoretical proliferative and oncogenic risk; circadian shift and daytime sedation; immunogenic and allergic reactions; unknown effects in pregnancy and early development

Monitoring

Marker Target Why
Complete blood count with differential Haemoglobin 13.5–15.0 g/dL (men), 12.5–14.5 g/dL (women); white cells 4.5–7.5 ×10⁹/L; platelets 200–350 ×10⁹/L Detects the suppression of blood cell production reported in the one human study that looked
Homocysteine 5–7 µmol/L Identifies the metabolic state in which the strongest animal benefit was shown
High-sensitivity C-reactive protein Below 0.5 mg/L Tracks low-grade inflammation as a general marker of physiological stress load
Urinary 8-hydroxy-2'-deoxyguanosine Lowest quartile for the assay's reference population Directly tests the antioxidant claim against the conflicting pro-oxidant finding
Comprehensive metabolic panel including estimated filtration rate Filtration rate above 90 mL/min/1.73 m²; alanine aminotransferase below 25 U/L (men) and below 20 U/L (women) Establishes clearance capacity for peptide fragments and any contaminants before exposure
Urinary 6-sulfatoxymelatonin, overnight Age-appropriate nocturnal rise present, with a clear day-night difference Tests whether any pineal effect is occurring, and detects melatonin adulteration of the product
Morning cortisol and DHEA-S Cortisol 10–15 µg/dL at 8 a.m.; DHEA-S in the upper third of the age-adjusted range Quantifies the stress-adaptation axis targeted by the occupational studies
Fasting glucose and fasting insulin Glucose 75–85 mg/dL; insulin below 5 µIU/mL Provides a general metabolic baseline against which any unexpected change can be judged

Cadence: Full baseline panel before the first dose, ideally within two weeks of starting; complete blood count and the oxidative damage marker repeated four weeks after the end of each course; full panel at six months, then every 6 to 12 months where courses are repeated.

Qualitative Assessment

  • Rapid eye movement and deep sleep duration, measured objectively by a wearable or under-mattress sensor
  • Sleep onset latency and number of night-time awakenings
  • Morning alertness within 30 minutes of waking
  • Sustained cognitive clarity through the afternoon
  • Emotional reactivity and recovery from stressors
  • Daytime energy and exercise tolerance
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.